AQST logo

AQST
Aquestive Therapeutics Inc

12,702
Mkt Cap
$519.91M
Volume
1.72M
52W High
$7.55
52W Low
$2.12
PE Ratio
-5.48
AQST Fundamentals
Price
$4.23
Prev Close
$4.26
Open
$4.13
50D MA
$4.34
Beta
1.31
Avg. Volume
5.89M
EPS (Annual)
-$0.7836
P/B
-15.44
Rev/Employee
$303,027.21
$701.02
Loading...
Loading...
News
all
press releases
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Aquestive Therapeutics
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST). This press release...
Business Wire·6h ago
News Placeholder
More News
News Placeholder
Investor Notice: Robbins LLP Informs Investors of the Aquestive Therapeutics, Inc. Class Action Lawsuit
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16...
Business Wire·21h ago
News Placeholder
Aquestive Therapeutics Q4 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) executives used the company's fourth-quarter 2025 earnings call to outline a path forward for Anaphylm, its orally delivered epinephrine product candidate...
MarketBeat·21h ago
News Placeholder
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors...
PR Newswire·1d ago
News Placeholder
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·2d ago
News Placeholder
Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -100.00% and -2.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
Aquestive Therapeutics (NASDAQ:AQST) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts...
MarketBeat·2d ago
News Placeholder
Harrow (HROW) Misses Q4 Earnings Estimates
Harrow (HROW) delivered earnings and revenue surprises of -34.46% and +0.33%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors...
PR Newswire·6d ago
News Placeholder
Aquestive Therapeutics Touts Anaphylm, Targets Q3 FDA Resubmission After CRL at Oppenheimer Conference
Aquestive Therapeutics (NASDAQ:AQST) executives outlined the company's near-term regulatory plans and longer-term platform strategy during a presentation at Oppenheimer's 36th Annual Healthcare Life...
MarketBeat·8d ago
<
1
2
...
>

Latest AQST News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.